OR WAIT 15 SECS
The European patent office has granted a patent entitled ?Proteome-wide quantification of small molecule binding to cellular target proteins? to German company, KINAXO Biotechnologies.
The European patent office has granted a patent entitled “Proteome-wide quantification of small molecule binding to cellular target proteins” to German company, KINAXO Biotechnologies.
“The granted patent emphasizes our leadership in providing chemical proteomics solutions for research and development,” says Henrik Daub, KINAXO’s CTO and main inventor of the patent. He says that the company delivers “powerful insights into cellular small molecule target interactions. Such knowledge significantly supports decision-making at various stages of the drug development process.”
The patent covers Cellular Target Profiling, KinAffinity and Epigenetics Target Profiling technologies. According to the company, Cellular Target Profiling enables comprehensive selectivity analysis and prediction of off-target liabilities for compounds with an unclear target spectrum. KinAffinity and Epigenetics Target Profiling are reported to deliver high quality, native selectivity data for kinase inhibitors or epigenetic drugs.
Patent applications in the United States and Japan are pending.
For more information visit www.kinaxo.com